NCT Number: NCT02834078
Effect of BGG on Glucose Metabolism and Other Markers of Metabolic Syndrome
According to the International Diabetes Federation, one in every 12 individuals is a diabetic (about 8% of the world population). Major risk factors of diabetes are all the aspects of modern life which include obesity, over-weight, high-risk behavior like smoking, alcohol, multiple drug use-recreational or prescribed, environmental risk factors like inactivity and lack of exercise. However there is a window of opportunity between health and disease, which is pre-diabetes.
Pre-diabetes has been defined by American Diabetes Association as Impaired Glucose Tolerance (IGT) which is 7.8 -11.0 mmol/l, Impaired Fasting Glucose Test (IFT) which is 5.6-6.9mmol/l and now added Glycosylated Hemoglobin (HbA1c) of 5.7% to 6.4%.
Though there are plenty of drugs available for significantly impaired glucose metabolism (including oral hypoglycemic agents and insulin), their use in marginally impaired glucose metabolism is questionable due to risk of untoward hypoglycemia.
On the other hand, herbal products like curcumin, as a single ingredient has poor bioavailability problem that restricts its use as standalone treatment. Inulin works as pre-biotic and help to maintain gut microbiota which is considered as precursor for progress of prediabetes to diabetes. However, it does not have any role in primary pathophysiology of impaired glucose metabolism, i.e. pancreatic β cell dysfunction, insulin resistance, hepatic gluconeogenesis or intestinal glucose absorption. Resveratrol and omega-3 basically work on anti-oxidant pathways.
None of these popular ingredients has been studied for their role in structural and functional health of pancreatic β cells which is very important for prediction of further progress of marginally impaired glucose metabolism to significantly impaired glucose metabolism.
It is an unmet need to develop a product which not only improves insulin sensitivity, but also help to preserve the structural and functional health of pancreatic β cells. It also needs to improve overall metabolic and endothelial health of the person considering the close association between impaired glucose metabolism and these parameters.
The proposed supplement - "Berberine GlucoGold "- is an improved version of successfully marketed supplement - Berberine GlucoDefense. It has a balanced composition in which all the ingredients complement each other in such a way that along with the individual role in glucose metabolism it also takes care of overall bioavailability and stability of the supplement. As per the previous data on ingredients, the supplement is also expected to preserve the structural and functional health of pancreatic β cells. The ingredients are also known to have positive effect on overall metabolic and endothelial health. Thus BGG has been developed to address the unmet needs in the area of glucose metabolism and overall metabolic health.
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year–60 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Able and willing to provide informed consent.
- Treatment naïve male-female aged 20-60 years of age.
- BMI ≥ 25 kg/m²
- Oral glucose tolerance test (OGTT) ≥140 and ≤250 mg/dl (pre-diabetes and early diagnosed diabetes within 45 days of diagnosis)
- Patient with chronic stable illness can be included ONLY IF he/she is currently NOT on any of the medications included in prohibited list of medicines.
- Currently on herbal supplements can be included after a wash-out period of 7 days.
- Subjects willing to abstain from nicotine and alcohol in the duration of the study.
Exclusion criteria
- Subjects with OGTT<140 mg/dl or ≥ 250 mg/dl
- Current treatment with diabetes medications, including metformin
- Current treatment with glucocorticoids
- History of clinically significant hematological, hepatic or renal diseases, as per investigator discretion
- Uncontrolled chronic disease
- Hormonal Disorders
- Subjects on Steroids
- Subjects on Statins
- Chronic inflammatory diseases requiring any medication
- Migraine, Sinusitis
- Subjects Consuming NSAIDS for long term
- Medications include the drugs of prohibited range.
- Pregnant and lactating females.
- Subjects addicted to nicotine, alcohol or any other recreational drug.
- Subjects who are planning to fast for more than 4 days/ per month during the study.
Treatment and study plan
Placebo
OtherPrimary outcomes
-
Change in Oral Disposition Index
Time frame: Day 0, Day 28, Day 56 and Day 84
-
Change in Glycated hemoglobin
Time frame: Day 0, Day 28, Day 56 and Day 84
Secondary outcomes
-
Change in Fasting blood sugar
Time frame: Day 0, Day 28, Day 56 and Day 84
-
Change in Body Mass Index
Time frame: Day 0, Day 28, Day 56 and Day 84
Sponsors and collaborators
Lead sponsor
Vedic Lifesciences Pvt. Ltd.
Industry
Collaborators
- Healthy Directions, LLC
Registry information
Official study title
Effect of 'Berberine Glucogold' [BGG] on Glucose Metabolism in Individuals With Marginally Impaired Glucose Metabolism Along With Other Markers of Metabolic Syndrome
Acronym: Glucogold
Important dates
- Study start
- 2015
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Jul 15, 2016
- Registry last updated
- Jul 15, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Type 2 Diabetes Primary Prevention for At Risk Girls
NCT00063674
Adherence Interventions, Behavior
Palo Alto, California, United States
View Trial DetailsPrecision Diets for Diabetes Prevention
NCT03919877
Diabetes Mellitus, Diabetes Mellitus, Type 2
Stanford, California, United States
View Trial DetailsComparative Effects of Exercise and Metformin on Glycemic Control in Prediabetic Adults
NCT07061496
Behavior, Glucose Intolerance
Nowshera, Pakistan
View Trial DetailsAbscisic Acid Effects on Glucose Homeostasis and Insulin Sensitivity
NCT04722354
Glucose Intolerance, Glucose Metabolism Disorders
Orlando, Florida, United States
View Trial Details